Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule.
作者信息
Abrouk Michael, Beroukhim Kourosh, Nakamura Mio, Zhu Tian Hao, Farahnik Benjamin, Singh Rasnik, Brodsky Merrick, Lee Kristina, Koo John, Bhutani Tina
机构信息
Irvine School of Medicine, University of California, Irvine, CA.
David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA.
出版信息
Int J Womens Dermatol. 2016 Mar 2;2(2):62-64. doi: 10.1016/j.ijwd.2016.02.001. eCollection 2016 Jun.
Abstract
摘要
相似文献
1
Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule.基于新的妊娠及哺乳期用药标签规则对银屑病生物制剂的考量
Int J Womens Dermatol. 2016 Mar 2;2(2):62-64. doi: 10.1016/j.ijwd.2016.02.001. eCollection 2016 Jun.
2
Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule.基于新的妊娠和哺乳期标签规则对银屑病生物制剂的考量
Int J Womens Dermatol. 2017 Feb 16;3(1 Suppl):S67-S69. doi: 10.1016/j.ijwd.2017.02.014. eCollection 2017 Mar.
3
Update on biologic safety for patients with psoriasis during pregnancy.银屑病患者孕期生物制剂安全性的最新进展
Int J Womens Dermatol. 2017 Feb 4;3(1):21-25. doi: 10.1016/j.ijwd.2016.12.003. eCollection 2017 Mar.
4
5
The 2015 US Food and Drug Administration Pregnancy and Lactation Labeling Rule.2015年美国食品药品监督管理局妊娠及哺乳期用药标签规则
J Midwifery Womens Health. 2017 May;62(3):308-316. doi: 10.1111/jmwh.12611. Epub 2017 May 29.
6
Impact of the Pregnancy and Lactation Labeling Rule (PLLR) on Practicing Dermatologists.妊娠和哺乳期标签规则（PLLR）对皮肤科执业医生的影响。
Dermatol Online J. 2015 Nov 18;21(11):13030/qt46c4m2tw.
7
Medication use in pregnancy and the pregnancy and lactation labeling rule.孕期用药及妊娠和哺乳期标签规则
Clin Pharmacol Ther. 2016 Jul;100(1):23-5. doi: 10.1002/cpt.380. Epub 2016 May 9.
8
Recent changes in pregnancy and lactation labeling: retirement of risk categories.妊娠和哺乳期标签的近期变化：风险分类的停用
Pharmacotherapy. 2014;34(4):389-95. doi: 10.1002/phar.1385. Epub 2014 Jan 4.
9
Considerations for assessing the cost of biologic agents in the treatment of psoriasis.评估生物制剂治疗银屑病成本的考量因素。
J Manag Care Pharm. 2004 Jun;10(3 Suppl B):S38-41.
10
An overview of upcoming changes in pregnancy and lactation labeling information.孕期及哺乳期用药标签信息的近期变化概述。
Pharm Pract (Granada). 2015 Apr-Jun;13(2):605. doi: 10.18549/pharmpract.2015.02.605. Epub 2015 Jun 15.
引用本文的文献
1
Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review.伴有合并症和特殊人群的中重度银屑病的生物治疗算法：综述。
Am J Clin Dermatol. 2021 Jul;22(4):425-442. doi: 10.1007/s40257-021-00603-w. Epub 2021 Apr 16.
2
Diagnostic and therapeutic guidelines for plaque psoriasis - Brazilian Society of Dermatology.斑块状银屑病的诊断和治疗指南 - 巴西皮肤病学会
An Bras Dermatol. 2019 Apr;94(2 Suppl 1):76-107. doi: 10.1590/abd1806-4841.2019940211. Epub 2019 Jun 30.
本文引用的文献
1
Preventing hepatitis B reactivation associated with immunosuppressive drug treatments for psoriasis.预防与银屑病免疫抑制药物治疗相关的乙型肝炎再激活
J Am Acad Dermatol. 2015 Nov;73(5):881-2. doi: 10.1016/j.jaad.2015.07.023.
2
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis.比较布罗达芦单抗与乌司奴单抗治疗银屑病的 3 期研究。
N Engl J Med. 2015 Oct;373(14):1318-28. doi: 10.1056/NEJMoa1503824.
3
Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials.在中度至重度银屑病中比较依奇珠单抗与依那西普或安慰剂的疗效（UNCOVER-2 和 UNCOVER-3）：两项 3 期随机临床试验的结果。
Lancet. 2015 Aug 8;386(9993):541-51. doi: 10.1016/S0140-6736(15)60125-8. Epub 2015 Jun 10.
4
New systemic therapies for psoriasis.银屑病的新型全身治疗方法。
Cutis. 2015 Mar;95(3):155-60.
5
6
Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up.乌司奴单抗在中重度斑块状银屑病患者中的长期疗效和安全性：来自 PHOENIX 2 研究长达 5 年随访的结果。
Br J Dermatol. 2015;172(5):1371-83. doi: 10.1111/bjd.13469. Epub 2015 Mar 22.
7
Trends in pregnancy labeling and data quality for US-approved pharmaceuticals.美国获批药品的妊娠标签及数据质量趋势
Am J Obstet Gynecol. 2014 Dec;211(6):690.e1-11. doi: 10.1016/j.ajog.2014.06.013. Epub 2014 Jun 6.
8
Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events.阿达木单抗、依那西普和英夫利昔单抗的安全性概况：一项在自发报告不良事件数据库中使用不成比例性测量方法的药物警戒研究。
J Clin Pharm Ther. 2014 Jun;39(3):307-13. doi: 10.1111/jcpt.12148. Epub 2014 Mar 17.
9
Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation.妊娠或哺乳期银屑病患者的治疗选择综述：来自全国银屑病基金会医学委员会。
J Am Acad Dermatol. 2012 Sep;67(3):459-77. doi: 10.1016/j.jaad.2011.07.039. Epub 2011 Oct 22.
10
[Conception and course of eight pregnancies in five women on TNF blocker etanercept treatment].
Z Rheumatol. 2010 Dec;69(10):903-9. doi: 10.1007/s00393-010-0652-y.
Zotero 插件